摘要
目的评价美罗培南在治疗肿瘤疾病合并中重度感染时的l临床疗效及安全性。方法采用回顾性分析方法，分析急性白血病等80例合并感染患儿应用美罗培南的疗效，剂量为每次10～20mg／kg，1次／8～12h静脉滴注，疗程〈10～14d。结果美罗培南治疗本组血液病合并感染的有效率为78．8％，在合并败血症5例中，4例有效，中性粒细胞绝对值〈0．5×10^9／L者，有效率达77．0％，不良反应发生率为0。结论美罗培南在治疗血液系统疾病合并感染疗效显著而且安全性好。
OBJECTIVE To analyze the treating efficacy of meropenem on blood tumor combined with the infection in children. METHODS A retrospective study protocol was adopted, totally 80 acute leukemia and other subjects complicated with infection were observed. The dosage of meropenem was 10-20 mg/kg, q8-12 h for all the patients and the treatment course in most patients was less than 10-14 days. RESULTS The effectiveness rate was 78. 8%. The effectiveness rate was 80 % for hematological system diseases complicated with septicemia and was 77.0 % for hematological system diseases complicated with agranulocytosis. The occurrence rate of side effect of meropenem in this group was 0. CONCLUSIONS Meropenem is significantly effective and safe in the treatment of hematological system diseases complicated with infections.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2007年第2期201-202,共2页
Chinese Journal of Nosocomiology
